Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company is headquartered in La Jolla, California and currently employs 50 full-time employees. The company went IPO on 2021-03-12. The firm is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). The company is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The firm plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. The company is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The firm is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.

Industry: Pharmaceutical Preparations Peers: TherapeuticsMD Inc Anebulo Pharmaceuticals Inc Aquestive Therapeutics Inc Clearside Biomedical, Inc Hyperion DeFi Inc Johnson & Johnson Medicine Man Technologies, Inc. Odonate Therapeutics, Inc. SCYNEXIS Inc